Biogen
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
As of today, Biogen(BIIB) shares are valued at $192.85. The company's market cap stands at 28.43B, with a P/E ratio of 22.89.
As of 2026-02-09, Biogen(BIIB) stock has fluctuated between $191.88 and $201.00. The current price stands at $192.85, placing the stock +0.5% above today's low and -4.1% off the high.
The Biogen(BIIB)'s current trading volume is 2.1M, compared to an average daily volume of 1.66M.
During the past year, Biogen(BIIB) stock moved between $110.04 at its lowest and $202.41 at its peak.
During the past year, Biogen(BIIB) stock moved between $110.04 at its lowest and $202.41 at its peak.
BIIB News
Biogen Inc (NASDAQ:BIIB) reported better-than-expected fourth-quarter results, prompting analysts to share insights on the company’s trajectory. Wedbush analyst...
RBC Capital raised the firm’s price target on Biogen (BIIB) to $233 from $217 and keeps an Outperform rating on the shares. The key for the company this quarter...
Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings. The company posted quarterly adjusted EPS of $1.99, beating the conse...
Analyst ratings
54%
of 37 ratingsMore BIIB News
Eisai (ESAIY) and Biogen (BIIB) announced that the Biologics License Application, BLA, for the subcutaneous formulation of “Leqembi,” an anti-amyloid beta proto...
Bernstein analyst William Pickering raised the firm’s price target on Biogen (BIIB) to $201 from $191 and keeps a Market Perform rating on the shares. The firm...
UBS analyst Michael Yee maintained a Hold rating on Biogen on February 6 and set a price target of $185.00. Valentine's Day Sale - 70% Off Unlock hedge fund-lev...
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Biogen on February 6 and set a price target of $190.00. Terence Flynn has given his Hold ratin...
Biogen's high dose nusinersen (SPINRAZA) regimen for spinal muscular atrophy has published new clinical results in Nature Medicine and is currently under FDA re...
Key Points The biotech published its last set of financials for 2025. Its quarterly revenue and adjusted profitability declined, yet both still topped the con...
Biogen Inc. ((BIIB)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.